Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial evaluating TP-05 (lotilaner), an investigational oral systemic therapy aimed at preventing Lyme disease by killing infected ticks before transmission. The randomized, placebo-controlled trial will enroll approximately 700 adults at risk across endemic U.S. regions,…